What It Is
Crystagen is a short investigational peptide most often discussed in immune-system and thymus-related research. Patent literature identifies the sequence as H-Glu-Asp-Pro-OH, or glutamyl-aspartyl-proline, and describes it as having "immunogeroprotective" activity, a term used in that filing rather than an independently validated clinical designation.[1]
The name appears with several variants in the literature and product marketing, including Crystagen, Crystagen lingual, and peptide complex AC-6.[1] It sits within the same research tradition as other short bioregulator peptides tied to thymus and immune biology, such as Thymalin and Thymogen, though it is a distinct compound from each.
How It Works
Crystagen is proposed to act through general short-peptide mechanisms discussed in the bioregulator literature, including effects on cellular regulation, gene expression, and protein biosynthesis, potentially via interactions with DNA-associated processes.[5] Its relevance to immune research stems from the thymus, where T lymphocytes mature and whose output declines with age.[7][8]
The most specific Crystagen finding comes from a study of aging spleen tissue, which reported that Crystagen activated B cells without causing broader spleen-cell renewal, alongside several related peptides studied for immunoprotective effects.[2] That is a narrow, model-specific observation, not evidence of clinical immune benefit.
What the Research Shows
Crystagen-specific evidence is limited to patent documentation and one PubMed-indexed aging-spleen study; no dedicated human trial or ClinicalTrials.gov record was identified.[2] Broader context comes from related thymic-peptide literature, but a Cochrane review of thymic peptides in cancer patients, covering 26 trials and more than 2,700 participants, found no clear benefit in survival or tumor response, despite a suggestion of fewer severe infections.[10]
That review did not test Crystagen directly, but it illustrates a broader pattern: plausible immune mechanisms and preclinical activity have not reliably translated into confirmed patient benefit. Claims that Crystagen normalizes immunity, reverses immune aging, or aids recovery from infection, chemotherapy, or radiation are not supported by controlled human evidence.
Safety & Side Effects
Crystagen has no FDA-reviewed label, so there is no standardized data on adverse reactions, contraindications, or drug interactions. The absence of documented side effects reflects a lack of systematic study, not confirmed safety.
- Because Crystagen is framed as immune-active, extra caution applies for anyone with autoimmune disease, active infection, cancer treatment, transplant history, or immunosuppressant use
- Safety in pregnancy, breastfeeding, and pediatric populations has not been established
- Compounded or research-use peptide products can carry added risks around impurities, sterility, and inaccurate dosing when marketed directly to consumers[17]
Regulatory Status
Crystagen should be considered unapproved and investigational in the United States. No FDA-approved prescribing label, listing in Drugs@FDA, or entry in the Orange Book was identified during source review.[11][12]
FDA rules also distinguish drug claims from dietary-supplement claims: a product may describe general structure or function, but claims to diagnose, treat, cure, or prevent disease require drug-level approval, which Crystagen does not have.[14]
Naming Variants and Dosage Forms in the Literature
Crystagen appears under several names across patent filings, regional literature, and marketing, including Crystagen, Crystagen lingual, AC-6, and peptide complex AC-6, alongside its chemical name glutamyl-aspartyl-proline.[1] These variants are not proof of consistent composition, purity, or effect across products sold under them.
Patent literature describes a parenteral formulation with a broad studied dose range of roughly 0.01 to 100 micrograms per kilogram, alongside mentions of lingual and capsule delivery in product-style literature.[1] These figures describe patent claims and study protocols, not an approved dose, and should not be read as personal dosing guidance.